Freeline Therapeutics Holdings plc

NASDAQ:FRLN

6.48 (USD) • At close February 16, 2024
Bedrijfsnaam Freeline Therapeutics Holdings plc
Symbool FRLN
Munteenheid USD
Prijs 6.49
Beurswaarde 28,283,096
Dividendpercentage 0%
52-weken bereik 2.11 - 8.745
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael J. Parini J.D.
Website https://www.freeline.life

An error occurred while fetching data.

Over Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment

Vergelijkbare Aandelen

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

0.41 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

7.25 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

1.97 USD

OKYO Pharma Limited logo

OKYO Pharma Limited

OKYO

1.02 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

1.855 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.788 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)